These recently downgraded names are displaying both quantitative and technical deterioration.
After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.
The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.
These recently downgraded names are displaying both quantitative and technical deterioration.
The medical device maker had an attractive chart even before the takeover rumors.
On top of all the other best-selling drugs in the firm's stable, Mounjaro has game-changer type potential.
Here's where aggressive traders could go long.
Shares of the animal healthcare company are poised to run further.
Buyers have been acting more aggressively than sellers.
The stock of parent company WW International has had a tremendous run so far this year, but its charts indicate it may trim down a bit near term.
There are several things to be encouraged about on the charts. Here's how I'd play the stock.
Here's what the charts and indicators reveal after earnings.
Now may not be the time to enter the healthcare giant's stock based on the bigger picture painted by its charts.
Nothing sparks the animal spirits in the biotech sector like a significant acquisition.
The shares of the provider of virtual healthcare services could stage a modest comeback based on its technical signals.
Here's how to play this medical device company.
The status of the market has changed as seven of 11 sectors turn positive -- but not all sectors have pointed upward, so let's look at the charts for each.
Wrapping a covered call strategy around this defensive name adds downside protection while enhancing its yield.
Let's review the charts of PACB again.
After gaining a fundamental supporter, here's how aggressive traders could play the stock.
Let's see what the the charts and indicators look like.
BSX has rallied the past nine months.
The trading days between the gaps look like an island surrounded by water.
These recession-resilient names offer above-average dividend yields and decent growth prospects.
The tech giant's stock won a buy rating from Goldman Sachs, and its work on a medical innovation could be a game-changer.
Here's a way to trade Vir Biotechnology.
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login